Patents Examined by Niloofar Rahmani
  • 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
    Patent number: 12240846
    Abstract: The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).
    Type: Grant
    Filed: August 11, 2023
    Date of Patent: March 4, 2025
    Assignee: Enliven Inc.
    Inventors: Joseph P. Lyssikatos, Samuel Kintz, Li Ren
  • GLP-1R agonist and therapeutic method thereof
    Patent number: 12234236
    Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions,
    Type: Grant
    Filed: September 13, 2024
    Date of Patent: February 25, 2025
    Assignee: Ascletis Pharma (China) Co., Limited
    Inventors: Bin Liang, Jinzi Jason Wu, Bailing Yang
  • Method for preparing N-phenylpyrazole-1-carboxamides
    Patent number: 12234217
    Abstract: A method is disclosed for preparing compounds of Formula 1 by combining compounds of Formulae 2 and 3 and a sulfonyl chloride in a continuous process.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: February 25, 2025
    Assignees: FMC CORPORATION, FMC AGRO SINGAPORE PTE. LTD.
    Inventor: Steven T. Booth
  • Heterocyclic GLP-1 agonists
    Patent number: 12221442
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: January 26, 2024
    Date of Patent: February 11, 2025
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Weiqiang Xing, Haizhen Zhang, Xichen Lin, Hui Lei, Andrew Jennings
  • Inhibitors of NLRP3 inflammasome
    Patent number: 12215087
    Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: February 4, 2025
    Assignee: BioAge Labs, Inc.
    Inventors: George Hartman, Paul Humphries, Kevin Edward Leif Wilhelmsen
  • 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
    Patent number: 12213969
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: February 4, 2025
    Assignee: VALO HEALTH, INC.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Mary-Margaret Zablocki
  • Anti-cancer nuclear hormone receptor-targeting compounds
    Patent number: 12208141
    Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: January 28, 2025
    Assignee: NUVATION BIO INC.
    Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
  • FGFR3 inhibitor compounds
    Patent number: 12209086
    Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
    Type: Grant
    Filed: December 13, 2023
    Date of Patent: January 28, 2025
    Assignee: ELI LILLY AND COMPANY
    Inventors: Adedoyin David Abraham, Desta Doro Bume, Kevin Ronald Condroski, Robert Alan Hazlitt, Timothy Scott Kercher, Andrew Terrance Metcalf, Kaveri Balan Urkalan, Shane Michael Walls, Andrew Karl Dilger
  • Five- and six-membered compound, and preparation method therefor and pharmaceutical composition and use thereof
    Patent number: 12195479
    Abstract: A five-membered-fused six-membered compound, and a preparation method therefor and a pharmaceutical composition and the use thereof. The five- and six-membered compound is a compound as shown in formula I, II or III. The compound has an inhibitory effect on FLT3 and/or IRAK4.
    Type: Grant
    Filed: December 19, 2023
    Date of Patent: January 14, 2025
    Assignee: HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Jason Shaoyun Xiang, Lei Wu, Rui Xu, Qiang Zhang, Gang Yang, Michael Xiang, Mixue Tong, Camille Xiang, Yuxin Liu, Suyue Wang, Rui Yang
  • Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof
    Patent number: 12195459
    Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.
    Type: Grant
    Filed: April 24, 2024
    Date of Patent: January 14, 2025
    Assignee: Tiger Biotherapeutics Inc.
    Inventors: Robert Luo, Ji Liu, Pin Huang, Jie Su, Yan Feng, Ke Liu, Jie Fan, Wei He, Yimin Qian
  • Polyheterocyclic compounds as METTL3 inhibitors
    Patent number: 12195458
    Abstract: The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z?? (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: January 14, 2025
    Assignee: Storm Therapeutics Limited
    Inventors: Wesley Peter Blackaby, Elizabeth Jane Thomas, David James Hardick, Jon Shepherd, Frederick Arthur Brookfield, Christian Bubert, Mark Peter Ridgill
  • Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
    Patent number: 12195460
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Grant
    Filed: July 3, 2024
    Date of Patent: January 14, 2025
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventor: Stéphane Dorich
  • Pyrrolo-dipyridine compounds
    Patent number: 12195461
    Abstract: In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id.
    Type: Grant
    Filed: March 7, 2023
    Date of Patent: January 14, 2025
    Assignee: OssiFi Therapeutics LLC
    Inventors: Debra Ellies, F. Scott Kimball, Robert N. Young
  • Compounds as inhibitors of AXL
    Patent number: 12195482
    Abstract: Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.
    Type: Grant
    Filed: August 14, 2024
    Date of Patent: January 14, 2025
    Assignee: Arcus Biosciences, Inc.
    Inventors: Joel Worley Beatty, Corinne Nicole Foley, Balint Gal, Manjunath Lamani, Manmohan Reddy Leleti, Dillon Harding Miles, Srinivas Paladugu, Jay Patrick Powers, Shiwei Qu
  • Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators
    Patent number: 12172997
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: October 14, 2022
    Date of Patent: December 24, 2024
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Akinola Soyode-Johnson, Brice Stenne, Christa Chrovian, Christine Gelin, Andrew Samant, Michael A. Letavic, Curt Dvorak
  • Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
    Patent number: 12168657
    Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: December 17, 2024
    Assignee: Ventus Therapeutics U.S., Inc.
    Inventors: Stéphane Dorich, Amandine Chefson
  • Modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 12168009
    Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: December 17, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida-Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
  • Cycloalkylurea derivative
    Patent number: 12162872
    Abstract: The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin type 2 receptor, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.
    Type: Grant
    Filed: November 26, 2020
    Date of Patent: December 10, 2024
    Assignee: Sumitomo Pharma Co., Ltd.
    Inventors: Eiji Ideue, Masafumi Komiya, Shoukou Lee, Shunichiro Uesugi, Yuta Funakoshi
  • Process for the preparation of intermediates useful for making (2S,5R)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
    Patent number: 12162883
    Abstract: The invention is related to the preparation of protected piperidine carboxylates suitable for use as intermediates that lead, via a series of additional process steps, including a sulfation of a hydroxy urea compound, to the preparation of the beta lactamase inhibitor (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: December 10, 2024
    Assignees: Merck Sharp & Dohme LLC, Merck Sharp & Dohme (UK)
    Inventors: John Y. L. Chung, Tetsuji Itoh, Jungchul Kim, Jacob Henry Waldman, Debra J. Wallace, Andrew Wood, Feng Xu, Andrew Gibson, Jeremy Peter Scott
  • Heterocyclic compound
    Patent number: 12152027
    Abstract: Provided is a compound that can have an effect of inhibiting MALT1 and is expected as useful as a prophylactic or therapeutic drug for cancer, etc. A compound represented by formula (I) [wherein each symbol is as defined in the description], a salt thereof, or a cocrystal, a hydrate or a solvate of the same.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: November 26, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu Hirayama, Yoshiteru Ito, Noriyuki Nii, Youichi Kawakita, Shinichi Imamura